Press Releases

Month Year

Month Year

Investor Alerts

Nov 6, 2024

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Oct 30, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
Oct 21, 2024

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Oct 15, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
Oct 3, 2024

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
Sep 30, 2024

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
Sep 26, 2024

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
Sep 4, 2024

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
Aug 28, 2024

Trevi Therapeutics to Participate in September Investor and Medical Conferences
Aug 8, 2024

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
Aug 1, 2024

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024
Jul 2, 2024

Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
May 9, 2024

Trevi Therapeutics to Participate in Upcoming Conferences
May 7, 2024

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 1, 2024

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Apr 9, 2024

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Apr 4, 2024

Trevi Therapeutics to Participate in Upcoming April Events
Apr 2, 2024

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Mar 20, 2024

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Mar 13, 2024

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
Feb 28, 2024

Trevi Therapeutics to Participate in Upcoming March Events
Feb 6, 2024

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan 4, 2024

Trevi Therapeutics Provides Business Updates
Dec 5, 2023

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
Nov 9, 2023

Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update

Show per page

Media Contact

Katie McManus
(203) 903-9627
k.mcmanus@trevitherapeutics.com

Trevi Therapeutics
195 Church Street, 14th Floor
New Haven, CT 06510
map